EUVIMEDEUVIMED entdecken
Crossref

Luliconazole Potentiates Efficacy of Miltefosine Against Leishmania donovani

Niva Singh, Mansi Rani, Hara Prasad Mandal, Raju Yadav, Ashiq Hussain Bhat, Dayakar Alti, Shubhankar Kumar Singh

Drug Development Research · 2026

DOI: 10.1002/ddr.70337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Niva Singh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Parasite Immunology Lab, Microbiology Division, Rajendra Memorial Research Institute of Medical Sciences (Indian Council of Medical Research), Patna,…. Hauptthemen laut MEDLINE: Leishmania donovani, Phosphorylcholine, Antiprotozoal Agents, Imidazoles. Die Arbeit nennt 82 Literaturangaben. Gefördert von: Department of Science and Technology, Ministry of Science and Technology, India, ICMR-Rajendra Memorial Research Institute of Medical Sciences, Department of Science and Technology, Government of Kerala.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Visceral leishmaniasis is a vector‐mediated parasitic disease caused by Leishmania donovani . Its treatment relies on chemotherapy with limited options. Existing drugs face significant challenges, including low efficacy, high relapse rates, toxicity, and cost. Therefore, exploring novel chemotherapeutic strategies identified as newer drugs targeting L. donovani CYP51 either alone or in combination with Miltefosine, which presents a promising alternative to current therapy. Here, we have evaluated the antileishmanial potential of an azole drug, luliconazole, which was previously demonstrated to target the sterol biosynthesis pathway in Leishmania major , in combination with conventional antileishmanial agents. Luliconazole exhibited significant inhibitory activity against both extracellular and intracellular L. donovani , with half‐maximal inhibitory concentrations of 4.67 and 6.24 µM, respectively. Notably, the addition of miltefosine and luliconazole combinations resulted in a synergistic effect, reducing the effective doses by 3.26‐ and 5.62‐fold compared to monotherapy with miltefosine and luliconazole, respectively. Conversely, the combination of luliconazole with Amphotericin B yielded antagonistic effects. A significant increase in nitric oxide by the parasite‐infected macrophages after luliconazole treatment underscores its leishmanicidal potential. Evaluation of host cell cytotoxicity, hemolytic assays, and oxidative burst affirmed the safety of luliconazole. This study is limited to in vitro intracellular amastigote. These findings highlight the efficacy of luliconazole, particularly in combination with miltefosine. Further investigations including formulation development and in vivo validation, are needed to assess the translational potential. This is the first study to demonstrate that luliconazole enhances miltefosine efficacy against L. donovani .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmania donovaniPhosphorylcholineAntiprotozoal AgentsImidazolesDrug SynergismAnimalsHumansMacrophagesLeishmaniasis, Visceral

Stichwörter der Autor:innen

Leishmania donovaniamphotericin Bluliconazolemiltefsoinesynergy

Substanzen

miltefosinePhosphorylcholineAntiprotozoal AgentsImidazolesluliconazole

Autor:innen und Institutionen

  • Parasite Immunology Lab, Microbiology Division, Rajendra Memorial Research Institute of Medical Sciences (Indian Council of Medical Research), Patna, Bihar, India.
  • Department of Zoology, University of Calcutta, Kolkata, India.
  • Biostatistics Division, Rajendra Memorial Research Institute of Medical Sciences (Indian Council of Medical Research), Patna, Bihar, India.
  • Immunology Division, Rajendra Memorial Research Institute of Medical Sciences (Indian Council of Medical Research), Patna, Bihar, India.
  • Academy of Scientific and Innovative Research (AcSIR), CSIR-Human Resource Development Centre (CSIR-HRDC) Campus, Ghaziabad, Uttar Pradesh, India.

Förderung

  • Department of Science and Technology, Ministry of Science and Technology, India
  • ICMR-Rajendra Memorial Research Institute of Medical Sciences
  • Department of Science and Technology, Government of Kerala

Zitieren

APA

Singh, N., Rani, M., Mandal, H. P., Yadav, R., Bhat, A. H., Alti, D., & Singh, S. K. (2026). Luliconazole Potentiates Efficacy of Miltefosine Against Leishmania donovani. Drug Development Research. https://doi.org/10.1002/ddr.70337

Vancouver

Singh N, Rani M, Mandal HP, Yadav R, Bhat AH, Alti D, et al. Luliconazole Potentiates Efficacy of Miltefosine Against Leishmania donovani. Drug Development Research. 2026. doi:10.1002/ddr.70337

BibTeX
@article{Singh2026,
  author = {Singh, Niva and Rani, Mansi and Mandal, Hara Prasad and Yadav, Raju and Bhat, Ashiq Hussain and Alti, Dayakar and Singh, Shubhankar Kumar},
  title = {Luliconazole Potentiates Efficacy of Miltefosine Against Leishmania donovani},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70337}
}
Kostenlos starten →